Pharma CEOs

The top 20 highest-paid biopharma CEOs of 2018
The top 20 highest-paid biopharma CEOs of 2018
Fierce Pharma
executive pay
Pharma CEOs
Flag link:
Sanofi's Leadership Transition: What You Need To Know
Sanofi's Leadership Transition: What You Need To Know
Yahoo/Benzinga
Sanofi
Pharma CEOs
Paul Hudson
Olivier Brandicourt
Flag link:
A struggling Sanofi is preparing to hire Novartis senior pharma exec Paul Hudson as new CEO, replacing Brandicourt -- report
A struggling Sanofi is preparing to hire Novartis senior pharma exec Paul Hudson as new CEO, replacing Brandicourt -- report
Endpoints
Sanofi
Pharma CEOs
Novartis
Paul Hudson
Olivier Brandicourt
Flag link:
From BIO meeting, Merck CEO Ken Frazier defends capitalism, drug industry
From BIO meeting, Merck CEO Ken Frazier defends capitalism, drug industry
Biopharma Dive
Merck
Pharma CEOs
Ken Frazier
BIO 2019
capitalism
drug pricing
Flag link:
Follow the money: How biopharma CEOs and workers got paid in 2018
Follow the money: How biopharma CEOs and workers got paid in 2018
Biopharma Dive
Pharma CEOs
executive pay
salaries
Flag link:
Novartis chief Vas Narasimhan wants you to know about the '25-plus’ blockbusters he has in the pipeline
Novartis chief Vas Narasimhan wants you to know about the '25-plus’ blockbusters he has in the pipeline
Endpoints
Novartis
R&D
Sandoz
Pharma CEOs
Vas Narasimhan
Flag link:
Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range
Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range
Yahoo/Reuters
Novartis
Pharma CEOs
Vas Narasimhan
gene therapy
SMA
drug pricing
Zolgensma
Flag link:
Commentary: Novartis CEO: Gene therapy offers hope of cures in one treatment, but US needs new pricing and payment model
Commentary: Novartis CEO: Gene therapy offers hope of cures in one treatment, but US needs new pricing and payment model
CNBC
gene therapy
cancer
Novartis
Pharma CEOs
Vas Narasimhan
Flag link:
Merck CEO, Ken Frazier's Unusual Priority -- Science
Merck CEO, Ken Frazier's Unusual Priority -- Science
Forbes
Merck
Pharma CEOs
Ken Frazier
science
Flag link:
Allergan CEO Saunders hangs on to chairman's title, winning shareholder support — but not by a big enough margin to squelch critics
Allergan CEO Saunders hangs on to chairman's title, winning shareholder support — but not by a big enough margin to squelch critics
Endpoints
Allergan
Pharma CEOs
Brent Saunders
Flag link:
Novartis Poaches GSK Veteran as New Sandoz CEO
Novartis Poaches GSK Veteran as New Sandoz CEO
BioSpace
Novartis
Sandoz
generics
Pharma CEOs
Richard Saynor
GSK
Flag link:
Seattle Genetics CEO Clay Siegall's comp package soars to $18.1M, rivaling Big Pharma chiefs
Seattle Genetics CEO Clay Siegall's comp package soars to $18.1M, rivaling Big Pharma chiefs
Endpoints
Seattle Genetics
Pharma CEOs
executive pay
Flag link:
Struggling Insys swaps CEOs as Subsys marketing crackdown continues
Struggling Insys swaps CEOs as Subsys marketing crackdown continues
Fierce Pharma
INSYS Therapeutics
Subsys
Pharma CEOs
Andrew Long
Flag link:
Revenue plunges, stock takes a drubbing, but Teva CEO Kåre Schultz still grabs $32.5M in chart-topping compensation
Revenue plunges, stock takes a drubbing, but Teva CEO Kåre Schultz still grabs $32.5M in chart-topping compensation
Endpoints
Teva Pharmaceutical
Kåre Schultz
Pharma CEOs
executive pay
Flag link:
Biopharma CEOs Explain Problems With Biosimilars to Congress
Biopharma CEOs Explain Problems With Biosimilars to Congress
RAPS.org
biosimilars
Pharma CEOs
Flag link:
Bristol-Myers CEO: We’re ‘one step closer to creating that great company’ with Celgene
Bristol-Myers CEO: We’re ‘one step closer to creating that great company’ with Celgene
CNBC
M&A
Bristol-Myers Squibb
Celgene
Pharma CEOs
Giovanni Caforio
Flag link:
It’s a seller’s world in biotech M&A, and Novartis CEO Vas Narasimhan has his check book out and pen ready
It’s a seller’s world in biotech M&A, and Novartis CEO Vas Narasimhan has his check book out and pen ready
Endpoints
Novartis
M&A
Alcon
Pharma CEOs
Vas Narasimhan
Flag link:
Novartis CEO's $50 Billion of Deals Was Just the First Act
Novartis CEO's $50 Billion of Deals Was Just the First Act
Yahoo/Bloomberg
Novartis
M&A
Vas Narasimhan
Pharma CEOs
Flag link:
AbbVie shareholder joins the growing ranks of critics, calling for an independent chairman
AbbVie shareholder joins the growing ranks of critics, calling for an independent chairman
Endpoints
AbbVie
Humira
Richard Gonzalez
executive pay
Pharma CEOs
Flag link:
Alexion chief registers $16.5M in pay after a solid year, with a relatively low 74-to-1 ratio compared to a well paid staff
Alexion chief registers $16.5M in pay after a solid year, with a relatively low 74-to-1 ratio compared to a well paid staff
Endpoints
Alexion
Pharma CEOs
executive pay
Ludwig Hantson
Flag link:

Pages